In the second of a two-part podcast episode, Jeremie Calais, M.D., and Robert Flavell, M.D., discuss current and emerging alpha-emitting therapies, possible roles for artificial intelligence (AI), and what the future may hold for theranostic applications in patients with prostate cancer.